Global Digital Biomarkers Market Forecast 2035
According to the report, the global digital biomarkers market is likely to grow from USD 3.0 Billion in 2025 to USD 33.5 Billion in 2035 at a highest CAGR of 24.5% during the time period. The most important reasons which led to the development of the Digital Biomarkers industry worldwide are the combination of innovative technologies, increasing chronic illness burden, and the necessity to provide healthcare that is personalized. The growing intensity of diseases like heart diseases, diabetes, and nerve disorders has increased the necessity of constant monitoring, and the same allows digital biomarkers to be able to offer real-time, data-driven information to achieve improved patient outcomes. The popularity of smartphones, wearable technologies, and AI-enabled platforms in the context of collecting physiological and behavioral data make it possible to collect data with ease in a clinical and homecare environment, increasing accessibility. Moreover, pharmaceutical firms are incorporating digital biomarkers in clinical trials to enhance efficiency, lower costs, as well as speed up drugs development. The validation of digital endpoints is also gaining support by the regulatory bodies, boosting the level of trust and market penetration. Combined with an increase in investments in digital health startup companies and collaboration between medtech and technology companies, these are driving a healthy growth in the global digital biomarkers market.
“Key Driver, Restraint, and Growth Opportunity Shaping the Global Digital Biomarkers Market
One of the most evident forces influencing the international market of digital biomarkers is the increased use of remote patient monitoring solutions, especially following the COVID-19 pandemic, when health care providers and patients turn to the use of digital health tools to monitor the disease on a regular basis without the need to go to a clinic, which guarantees better access and up-to-date medical information.
The most significant limitation is the absence of standardized protocols and compatibility between different digital health platforms as fragmented data systems and a difference in compatibility with devices makes it difficult to integrate biomarkers into clinical workflows and, therefore, their scalability and their adoption across the healthcare systems.
One of the most important opportunities is the use of digital biomarkers to prevent healthcare, as the early identification of disease risks due to constant monitoring of vital parameters and behavioral changes will decrease the costs of treatment in the long term, promote preventive health measures, and establish new collaborations between insurers, providers, and technological organizations.
Expansion of Global Digital Biomarkers Market
“Rising chronic conditions, AI integration, and pharma collaborations are fueling the expansion of the global Digital Biomarkers market”
- The growth of the digital market of biomarkers is characterized by the increasing level of such chronic illnesses as diabetes, cardiovascular diseases, and neurological disorders that require monitoring and early diagnosis solutions. To illustrate, the International Diabetes Federation portrays that more than 537 million adults were living with diabetes in 2021, and there is massive demand to find non-invasive, real-time monitoring of biomarkers to be able to control the conditions more efficiently.
- One of the drivers of growth is the adoption of artificial intelligence (AI) and machine learning on digital biomarker platforms, which make them predictive and allow a more personalized approach. To improve clinical decision-making systems and to speed up its adoption in the developed healthcare systems, companies are adding AI-driven algorithms to wearable devices and mobile health applications to identify subtle changes in patient health patterns.
- Furthermore, the pharmaceutical companies and technology providers are making strategic partnerships in the market to enhance the market. Laboratories: As developers of drugs, there is more virtual reliance on the use of digital biomarkers in clinical trials to obtain continuous and patient-centric data that could not have been measured using traditional lab tests. As an example, digital health startups collaborating with biotech companies are simplifying the process of trials, cutting expenses, and making endpoints more accurate, creating a market growth in the global market.
Regional Analysis of Global Digital Biomarkers Market
- The necessity in digital biomarkers is the greatest in North America as the region has a well-developed healthcare infrastructure, embraces digital health technologies early, and spends a lot on healthcare. The area also enjoys strong regulatory backing including that of the U.S FDA encouraging the use of digital endpoints in clinical trials, which is speeding up adoption in the pharmaceutical and biotech sectors. Also, there is increased engagement with patients because of the high use of related devices such as smart watches, fitness trackers and remote patient monitoring equipment. North America has been dominant in this market, and the existence of major technological giants and digital health startups in partnership with healthcare providers further reinforces this dominance of the US.
- The future growth in digital biomarkers market will take place in Asia Pacific due to the increase in the number of chronic diseases, ageing population and initiatives by the government to digitize health care. The rising use of affordable wearable devices in countries like China, India and Japan, increased smart phone penetration and rising adoption of these devices are fueling the adoption of digital biomarker solutions. In addition, new opportunities are being generated by investments in AI-oriented research in healthcare and the increase in the number of clinical trials conducted by multinational pharmacological organizations in the region. Such a mix of digital transformation, modernization of the healthcare sector, and affordable acquisition of devices makes the Asia Pacific the fastest growing market in the world.
Prominent players operating in the global digital biomarkers market are Akili Interactive Labs, AliveCor Inc., Alphabet Inc. (Verily Life Sciences), Apple Inc., Bayer AG, Biogen Inc., Boston Scientific Corporation, Empatica Inc., Evidation Health, Fitbit (now part of Google), Garmin Ltd., GSK (GlaxoSmithKline), Hitachi Ltd., Human API, IBM Corporation, Koneksa Health, Mindstrong Health, Neurotrack Technologies Inc., Oura Health, Philips Healthcare, and Other Key Players.
The global digital biomarkers market has been segmented as follows:
Global Digital Biomarkers Market Analysis, by System Component
- Data Collection Tools
- Wearable Devices (Smartwatches, Fitness Trackers)
- Mobile Apps
- Ingestible Sensors
- Implantable Sensors
- Environmental Sensors
- Others
- Data Integration & Analytics Platforms
- Artificial Intelligence (AI) Tools
- Machine Learning Models
- Cloud-based Data Management
- Others
Global Digital Biomarkers Market Analysis, by Deployment Mode
Global Digital Biomarkers Market Analysis, by Type of Biomarker
- Physiological Biomarkers
- Heart Rate
- Blood Pressure
- Others
- Behavioral Biomarkers
- Sleep Patterns
- Speech
- Motor Activity
- Others
- Cognitive Biomarkers
- Biochemical Biomarkers
- Others
Global Digital Biomarkers Market Analysis, by Therapeutic Area
- Oncology
- Cardiology
- Endocrinology
- Neurology
- Psychiatry
- Pulmonology
- Others
Global Digital Biomarkers Market Analysis, by Phase of Development
- Discovery & Preclinical Research
- Clinical Development
- Post-market Monitoring & Real-world Evidence
Global Digital Biomarkers Market Analysis, by Application
- Cardiovascular Diseases
- Neurodegenerative Disorders (e.g., Parkinson’s, Alzheimer’s)
- Diabetes
- Respiratory Disorders (e.g., Asthma, COPD)
- Sleep and Movement Disorders
- Mental Health (e.g., Depression, Anxiety)
- Oncology
- Other Chronic Conditions
Global Digital Biomarkers Market Analysis, by End User
- Pharmaceutical & Biotech Companies
- Healthcare Providers
- Payers & Insurance Companies
- Research Organizations & Academic Institutions
- Patients & Consumers
- Others
Global Digital Biomarkers Market Analysis, by Region
- North America
- Europe
- Asia Pacific
- Middle East
- Africa
- South America
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact Us
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co